High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
- PMID: 18378853
- PMCID: PMC2396728
- DOI: 10.1182/blood-2007-11-124958
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study
Abstract
BAALC expression is considered an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML), but has yet to be investigated together with multiple other established prognostic molecular markers in CN-AML. We analyzed BAALC expression in 172 primary CN-AML patients younger than 60 years of age, treated similarly on CALGB protocols. High BAALC expression was associated with FLT3-ITD (P = .04), wild-type NPM1 (P < .001), mutated CEBPA (P = .003), MLL-PTD (P = .009), absent FLT3-TKD (P = .005), and high ERG expression (P = .05). In multivariable analysis, high BAALC expression independently predicted lower complete remission rates (P = .04) when adjusting for ERG expression and age, and shorter survival (P = .04) when adjusting for FLT3-ITD, NPM1, CEBPA, and white blood cell count. A gene-expression signature of 312 probe sets differentiating high from low BAALC expressers was identified. High BAALC expression was associated with overexpression of genes involved in drug resistance (MDR1) and stem cell markers (CD133, CD34, KIT). Global microRNA-expression analysis did not reveal significant differences between BAALC expression groups. However, an analysis of microRNAs that putatively target BAALC revealed a potentially interesting inverse association between expression of miR-148a and BAALC. We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile.
Figures


Similar articles
-
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.J Clin Oncol. 2007 Aug 1;25(22):3337-43. doi: 10.1200/JCO.2007.10.8720. Epub 2007 Jun 18. J Clin Oncol. 2007. PMID: 17577018
-
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Blood. 2010 Dec 16;116(25):5660-9. doi: 10.1182/blood-2010-06-290536. Epub 2010 Sep 14. Blood. 2010. PMID: 20841507 Free PMC article.
-
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.J Clin Oncol. 2009 Jul 1;27(19):3198-204. doi: 10.1200/JCO.2008.20.6110. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451432 Free PMC article.
-
The role of molecular tests in acute myelogenous leukemia treatment decisions.Curr Hematol Malig Rep. 2010 Apr;5(2):109-17. doi: 10.1007/s11899-010-0049-7. Curr Hematol Malig Rep. 2010. PMID: 20425404 Review.
-
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood. 2007 Jan 15;109(2):431-48. doi: 10.1182/blood-2006-06-001149. Epub 2006 Sep 7. Blood. 2007. PMID: 16960150 Free PMC article. Review.
Cited by
-
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.Blood. 2012 Sep 13;120(11):2297-306. doi: 10.1182/blood-2012-02-414425. Epub 2012 Aug 1. Blood. 2012. PMID: 22855599 Free PMC article. Clinical Trial.
-
The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia.Mol Cancer. 2010 Jan 27;9:18. doi: 10.1186/1476-4598-9-18. Mol Cancer. 2010. PMID: 20105281 Free PMC article.
-
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Haematologica. 2011 Oct;96(10):1488-95. doi: 10.3324/haematol.2011.041905. Epub 2011 Jun 9. Haematologica. 2011. PMID: 21659357 Free PMC article.
-
Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies.Int J Mol Sci. 2020 Apr 29;21(9):3141. doi: 10.3390/ijms21093141. Int J Mol Sci. 2020. PMID: 32365599 Free PMC article. Review.
-
Molecular signatures in acute myeloid leukemia.Curr Opin Hematol. 2009 Mar;16(2):64-9. doi: 10.1097/MOH.0b013e3283257b42. Curr Opin Hematol. 2009. PMID: 19468266 Free PMC article. Review.
References
-
- Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336. - PubMed
-
- Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320. - PubMed
-
- Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood. Rev. 2004;18:115–136. - PubMed
-
- Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res. 2001;61:7233–7239. - PubMed
-
- Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–4380. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA098933/CA/NCI NIH HHS/United States
- CA016058/CA/NCI NIH HHS/United States
- CA089341/CA/NCI NIH HHS/United States
- R01 CA089341/CA/NCI NIH HHS/United States
- CA077658/CA/NCI NIH HHS/United States
- U24 CA114725/CA/NCI NIH HHS/United States
- U10 CA101140/CA/NCI NIH HHS/United States
- R01 CA098933/CA/NCI NIH HHS/United States
- K01 CA096887/CA/NCI NIH HHS/United States
- P30 CA016058/CA/NCI NIH HHS/United States
- CA114725/CA/NCI NIH HHS/United States
- CA096887/CA/NCI NIH HHS/United States
- CA101140/CA/NCI NIH HHS/United States
- U10 CA077658/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous